You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Ascelia Pharma - Final outcome of rights issue
You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.
Meet and ask questions to CEO Magnus Corfitzen on 10 September 2024 at 2.00PM.
The company has secured approximately SEK 105 million in gross proceeds before issue costs. The issue was completed without guarantors.
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – Orviglance in Phase 3 and Oncoral in clinical development, but for the moment on hold. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 6 September 09.23AM.